Group 1 - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 3.57% on July 28, with a trading volume of 2 billion CNY [1] - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1] - As of July 25, 2024, the fund's latest share count was 2.299 billion, with a total size of 4.176 billion CNY, reflecting an increase of 481.58% in shares and 1005.40% in size year-to-date [1] Group 2 - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 81.63% during the management period [2] - The top holdings of the fund include Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant weightings such as 9.52% for Innovent Biologics and 9.47% for WuXi Biologics [2] - The fund's trading liquidity is notable, with a cumulative trading amount of 42.835 billion CNY over the last 20 trading days, averaging 2.142 billion CNY per day [1][2]

Group 1: Market Overview - The report highlights that the tariff concerns are gradually dissipating, leading to significant net inflows in Hong Kong Stock Connect trading [2][3] - The Hang Seng Index experienced a decline, closing at 25,388 points, down 278 points or 1.1%, with a trading volume of 281.8 billion HKD [2][3] - Northbound trading recorded a net inflow of nearly 20.2 billion HKD, an increase of 442.8% compared to the previous day [2][3] Group 2: Sector Performance - Among the 12 Hang Seng Composite Industry Indices, 2 sectors rose while 10 sectors fell, with the largest declines seen in consumer discretionary, financials, and materials, each down 1.87%, 1.09%, and 1.09% respectively [3] - The technology sector also saw a decline of 0.72% [3] Group 3: Company Analysis - Great Wall Motors - Great Wall Motors (2333.HK) is expected to achieve a revenue of 92.3 billion HKD in the first half of 2025, a year-on-year increase of 1.0%, with a net profit of 6.34 billion HKD, down 10.2% year-on-year [5] - In Q2 2025, the company reported a revenue of 52.35 billion HKD, a year-on-year increase of 7.8% and a quarter-on-quarter increase of 30.8%, with a net profit of 4.59 billion HKD, up 19.1% year-on-year and 161.9% quarter-on-quarter [5] - Q2 sales improved, reaching 313,000 units, a year-on-year increase of 10.1% and a quarter-on-quarter increase of 21.9% [5] Group 4: Future Outlook for Great Wall Motors - The company plans to launch multiple new models in the second half of 2025, focusing on hybrid and smart electric vehicles, which are expected to enhance sales [6] - The report maintains a target price of 18.0 HKD for Great Wall Motors, corresponding to a 10.3 times forecasted P/E ratio for 2025, with a buy rating [6]

Core Viewpoint - The performance of innovative drug ETFs in the A-share market has been strong, with significant increases in trading volume and price, indicating growing investor interest in the sector [1][3]. Group 1: ETF Performance - The Tianhong Innovative Drug ETF (517380) saw a half-day increase of 2.11%, with a trading volume of approximately 13.31 million yuan and a total size of 778 million units [3][6]. - Other innovative drug ETFs also performed well, with the Huatai-PB Innovative Drug ETF (517120) increasing by 1.99% and the Innovative Drug 50 ETF (159835) rising by 1.88% [2][6]. - The overall trading activity in the innovative drug ETFs was robust, with the Innovative Drug ETF (159992) achieving a half-day trading amount of nearly 300 million yuan [1][9]. Group 2: Index Tracking - The Hang Seng-Hushen Hong Kong Innovative Drug Selected 50 Index tracks 50 stocks listed in Shanghai, Shenzhen, or Hong Kong that have high R&D investment and strong momentum [4][6]. - The index aims to reflect the performance of the most representative stocks in the innovative drug industry, selected based on market capitalization [4][9]. - The China Securities Hong Kong-Shenzhen Innovative Drug Industry Index includes stocks from A-shares and eligible Hong Kong stocks, focusing on companies involved in innovative drug R&D and production [6][9]. Group 3: Major Holdings - Major stocks in the Hang Seng-Hushen Hong Kong Innovative Drug Selected 50 Index include Baijie Shenzhou (6160.HK) with a weight of 12.00%, WuXi AppTec (603259.SH) at 11.26%, and Hengrui Medicine (600276.SH) at 8.39% [5][10]. - The China Securities Innovative Drug Industry Index also features significant holdings such as WuXi AppTec (603259) with a weight of 12.58% and Hengrui Medicine (600276) at 9.51% [10].

Macro and Strategy Research - The report highlights a persistent "anti-involution" sentiment in the macroeconomic environment, with the U.S. manufacturing PMI falling to a new low since December 2024, while the service sector shows signs of recovery [2][3] - In the domestic context, various sectors including automotive, photovoltaic, cement, and steel are actively implementing measures to curb disorderly competition and promote industrial upgrades, significantly boosting market sentiment [4] - The upcoming Politburo meeting is expected to provide further insights into policy directions, particularly regarding the importance of "anti-involution" in addressing supply-demand imbalances [4] Fixed Income Research - The report notes that the bond market is under pressure, with the 10-year government bond yield rising above 1.7%, influenced by a tightening of the monetary environment and expectations of increased infrastructure investment [6][7] - The central bank has conducted a net withdrawal of over 500 billion yuan in the open market, leading to a noticeable increase in funding prices [7] - The issuance of bonds has seen weak subscription sentiment, with a total issuance of 90 bonds amounting to 940.9 billion yuan, indicating a continued lack of enthusiasm in the primary market [7] Industry Research - The report discusses the "anti-involution" in centralized procurement within the pharmaceutical and biotechnology sectors, emphasizing the need to focus on beneficiaries of optimized procurement rules [10] - Key industry news includes the approval of new treatments and the establishment of a biopharmaceutical industrial park in Pudong, which is expected to enhance the sector's growth [10][11] - The report indicates a positive performance in the pharmaceutical sector, with the Shanghai Composite Index rising by 2.53% and the pharmaceutical sector increasing by 2.94% during the week [11] - The report suggests that the innovation drug sector is supported by ongoing policy initiatives, and it recommends focusing on companies that are expected to benefit from these changes [11]

Market Performance - The Hang Seng Index rose 2.3% last week, closing at 25,388 points, marking a three-year high[1] - The Hang Seng Tech Index increased by 2.5%, closing at 5,677 points, breaking free from a stagnant period since May[1] - Average daily trading volume increased by 12.6% to HKD 287.9 billion, with net inflows of HKD 32.3 billion through the Stock Connect[1] Sector Analysis - The telecommunications sector was the only one to decline, while the composite, materials, and energy indices rose by 8.8%, 7.7%, and 5.4% respectively[1] - The automotive sector outperformed the market with an average increase of 3.8%, driven by regulatory support for healthy development[4] - The healthcare index rose by 0.8%, benefiting from government support for innovative drugs[4] Economic Indicators - The predicted PE ratio for the Hang Seng Index is at 11.1 times, within the 78.2% percentile over the past seven years, indicating high market sentiment and relative valuation[3] - The weighted risk premium based on 70% US Treasuries and 30% Chinese bonds is at its lowest since January 2021, suggesting a high valuation environment[3] Future Outlook - If trade agreements between the US and Europe materialize, along with domestic policy catalysts, the Hang Seng Index may continue its gradual recovery driven by fundamentals[2] - In the most optimistic scenario, the Hang Seng Index could reach 27,400 points if the Chinese 10-year bond yield is at 1.75% and the US 10-year yield remains at 4.4%[3]

Investment Rating - The report does not explicitly state an investment rating for the industry, but it provides insights into market performance and trends [2][4]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.9%, underperforming the Wind All A index (2.21%) but outperforming the CSI 300 index [2][7]. - The medical research outsourcing segment experienced the highest growth at 8.29%, while chemical preparations and other biological products faced declines of -2.02% and -0.58%, respectively [2][8]. - The Quark Health model achieved a significant milestone by passing the written assessment for chief physician in 12 core disciplines, marking a rapid development phase for medical AI models in China [2][11]. - State-owned equity funds are actively acquiring stakes in pharmaceutical companies, with notable transactions including the acquisition of Kanghua Biological and a significant stake in MicroPort Medical [2][11]. Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector rose by 1.9% from July 21 to July 25, 2025, with medical research outsourcing leading the gains at 8.29% [2][7]. - Individual stocks such as Haitai Biological (46.9%), Zhendong Pharmaceutical (42.9%), and Saily Medical (31.7%) saw significant increases, while *ST Suwu (-22.3%) and Yong'an Pharmaceutical (-13.7%) faced notable declines [2][10]. Industry News and Key Company Announcements Important Industry Events - The National Medical Insurance Administration announced new measures to optimize drug procurement, emphasizing quality over lowest price and launching a nationwide drug price comparison tool [2][11]. Industry News - Shanghai Biopharmaceutical M&A Fund is set to acquire shares in MicroPort Medical, becoming a strategic shareholder [2][11]. - Kangfang Biologics' new indication application for Ivoris monoclonal antibody has been accepted by the National Medical Products Administration [2][11]. Company Announcements - WuXi Biologics reported a positive mid-year earnings forecast, expecting a 16% revenue increase and a 3.6% rise in gross margin [2][14]. - The Quark Health model's capabilities continue to align closely with human physicians, marking a significant advancement in AI healthcare applications [2][14]. - WuXi AppTec and other companies reported substantial revenue growth, with WuXi AppTec expecting over 60% growth in the first half of 2025 [2][14].

Group 1: Trade Agreements and Economic Policies - Trump announced a trade agreement between the US and EU, imposing a 15% tariff and a $600 billion investment from the EU into the US, while the EU will implement 0% tariffs on US goods [11] - The US Commerce Secretary stated that the deadline for tariff increases on August 1 will not be extended, and the US will determine its chip tariff policy within two weeks [11] - The US is expected to impose anti-dumping duties on Canadian softwood lumber, with rates to be announced on August 8 [11] Group 2: Market Performance - International oil prices fell due to negative economic news and expectations of increased supply, with WTI crude oil down 1.67% to $64.85 per barrel and Brent crude down 1.41% to $67.60 per barrel [4] - US stock indices closed higher, with the Dow Jones up 0.47%, S&P 500 up 0.4%, and Nasdaq up 0.24% [4] - European stock indices showed mixed results, with Germany's DAX30 down 0.32% and the UK FTSE 100 down 0.2% [5] Group 3: Sector-Specific Developments - In Hong Kong, semiconductor stocks performed well, with Hua Hong Semiconductor rising 9% and SMIC up nearly 5%, while education and entertainment stocks faced declines [5] - In the A-share market, the semiconductor sector saw gains, with Zhangjiang Hi-Tech hitting the daily limit and Cambrian Technology rising over 12% [6] - The pharmaceutical outsourcing sector also showed strong performance, with WuXi Biologics up over 5% [5]

Core Insights - The dual antibody (dual-target) market is experiencing explosive growth in 2023, with major multinational corporations (MNCs) like Roche and Johnson & Johnson leading the charge [1][17] - Roche has successfully launched several dual antibodies in the Chinese market, including Glofitamab and Faricimab, while Johnson & Johnson's Amivantamab targets a $5 billion market in non-small cell lung cancer (NSCLC) [2][13] Group 1: Dual Antibodies in Hematological Malignancies - The dual antibody market began in 2014 with the FDA's accelerated approval of Blincyto for treating acute lymphoblastic leukemia, which generated $583 million in sales in 2022 [5] - Currently, most approved dual antibodies are focused on hematological malignancies, with a significant number targeting CD3 in various combinations [6][8] - The competition between dual antibodies and CAR-T therapies is intensifying, particularly in the CD3/CD20 target combination, which has over 10 candidates in development globally [8][9] Group 2: Broadening Applications in Solid Tumors - Dual antibodies are expanding into various indications, including genetic diseases and solid tumors, with significant potential in the latter [11] - Amivantamab, the first dual antibody approved for solid tumors, is projected to reach peak sales of $5 billion, supported by positive clinical data [13][15] - Roche's Faricimab has also made strides in ophthalmology, achieving $1.788 billion in sales in the first three quarters of 2023 due to its long-lasting efficacy [15] Group 3: Domestic Dual Antibody Development - The domestic dual antibody market is expected to enter a concentrated harvest period in 3-5 years, with over 20 candidates currently in development [18] - Domestic companies are increasingly pursuing international collaborations, with notable deals exceeding $1 billion in potential total transaction value [19] - The first domestic dual antibody, Kadofili monoclonal antibody, was approved in 2022, generating significant revenue and expanding its indications [21][22]

Group 1: Southbound Capital Flow - Southbound capital has significantly increased, with a net purchase of HKD 201.84 billion on a single day, bringing the total net purchase for the year to HKD 8200.28 billion, surpassing last year's total of HKD 8079 billion, marking a historical high for the same period [1][2] - The southbound capital has been the strongest inflow into Hong Kong stocks this year, marking the 25th consecutive month of net purchases [3] Group 2: Bond Market Dynamics - The bond market is facing redemption pressure, with nearly HKD 1000 billion redeemed in a single day, the largest since January's market correction [7] - The yield on ten-year government bonds has risen from 1.66% to 1.75%, indicating a trend of increasing interest rates [7] - Insurance institutions have reduced their holdings in government bonds for three consecutive months, with reductions of HKD 89 million, HKD 74 million, and HKD 12 million in April, May, and June respectively [7] Group 3: Equity Fund Trends - The total scale of public funds in China reached a record high of CNY 34.39 trillion by the end of June, with mixed funds showing signs of recovery after a period of decline [11] - Mixed funds saw an increase of CNY 121.3 billion in scale, reaching CNY 3.68 trillion, with a slight increase in shares [11][13] - The issuance of new mixed funds in June was significant, with 155 new funds launched, totaling 122.12 billion shares [11][13] Group 4: Money Market Fund Performance - Money market funds experienced a decline in both scale and shares in June, with reductions of CNY 167.5 billion and 164.5 billion shares respectively [15] - The yield on the largest money market fund, Yu'e Bao, has decreased from 1.58% in February to 1.09%, nearing a drop below 1% [15]

Core Viewpoint - The article emphasizes the ambition of Pudong New Area to become a global hub for innovative biopharmaceuticals, focusing on the development of "First-in-class," "First-in-China," and "First-in-Human" products, alongside significant growth in large-scale innovative drug companies and international market penetration [1][2]. Group 1: Industry Growth and Achievements - The biopharmaceutical industry in Pudong has seen rapid growth, with the industry scale increasing from 240.8 billion yuan in 2020 to 410 billion yuan in 2024, representing a compound annual growth rate of 14% [2]. - Pudong accounts for approximately 20% of the national innovative drug pipeline and 6% of the global pipeline, with 24 new drug approvals since 2020 [2]. - The region has achieved significant milestones in innovative products, including First-in-class and First-in-China drugs, with examples like the new target drug from Hualing Pharmaceutical and several stem cell and gene therapy products [2][3]. Group 2: Policy and Institutional Innovations - Pudong has implemented various policy measures to streamline clinical trials and product approvals, including a unified ethical review process for clinical studies [5][6]. - The area has introduced a recommendation catalog for innovative drugs and devices, with 75 products included, leading to a 63% year-on-year increase in usage of these products in local medical institutions [6]. - Ongoing reforms aim to enhance the efficiency of drug approvals and market access, including pilot programs for segmented production of biopharmaceuticals [6][7]. Group 3: Entrepreneurial Ecosystem for Scientists - Pudong aims to establish itself as a preferred location for scientific entrepreneurship by creating low-cost innovation incubation zones and fostering collaboration with universities and research institutions [9][10]. - The region's lower R&D costs and higher clinical trial efficiency compared to developed countries have attracted international recognition, with over 30 overseas authorizations in 2024 [9][10]. - The "nuclear explosion" zone in Pudong is designed to concentrate high-energy innovation entities, including incubators and research centers, to stimulate the growth of biopharmaceutical startups [10][11].